Protalix Biotherapeutics, Inc. (PLX)

Several events have influenced Protalix's stock price in the past six months. The Q2 2025 earnings report showed revenue beating estimates but EPS missing, leading to a stock decrease. The CHMP issued a negative opinion on Elfabrio's four-week dosing regimen, causing a significant stock plunge. The company released its Q1 2025 earnings. Gilad Mamlok was appointed as the new CFO. The company held its Annual General Meeting. In 2024, Protalix experienced a decrease in revenue and earnings compared to the previous year, with Q1 2024 showing decreased revenues from license and R&D services and from selling goods compared to Q1 2023.

Data on mean and median monthly returns for PLX stock is available to identify seasonal patterns in its stock performance. Specific details regarding demand seasonality for Protalix Biotherapeutics' products and services are not explicitly provided.

Protalix Biotherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system. The company operates in the Healthcare sector, specifically in Biotechnology and Biological Products, with a focus on Endocrinology and Metabolism Biopharmaceuticals. Its major commercial products include Elelyso for Gaucher disease and Elfabrio for Fabry disease. The company's pipeline includes PRX-115 for gout and PRX-119 for neutrophil extracellular traps diseases.

Protalix Biotherapeutics is headquartered in Hackensack, New Jersey, with operations in Carmiel, Israel. The company's commercial reach extends to the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. Collaborations with partners like Pfizer and Chiesi Farmaceutici S.p.A. have facilitated global commercialization in North America, Europe, and Latin America.

Protalix BioTherapeutics' brand reputation has been influenced by several developments. The company transitioned to profitability in Q2 2025, reporting a net income, and is noted as being debt-free with two approved assets and an advancing development portfolio, contributing positively to its reputation. However, the negative opinion from the CHMP of the European Medicines Agency regarding the every four-week dosing regimen of Elfabrio in the EU could negatively affect its reputation.

As of October 28, 2025, institutional investors own 16.5% of Protalix BioTherapeutics shares, while insiders hold 6.5% of the shares.